Actively Recruiting

Phase Not Applicable
Age: 45Years - 80Years
MALE
NCT06866041

Biological Markers and Advanced Imaging for Prostate Cancer Progression in Active Surveillance

Led by Università Vita-Salute San Raffaele · Updated on 2025-05-16

74

Participants Needed

1

Research Sites

251 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study aims to identify patients with low-risk prostate cancer (ISUP Grade Group 1) eligible for active surveillance who are at higher risk of upgrading to ISUP Grade Group 2 or higher at confirmatory biopsy one year after diagnosis. Patients with low-risk ISUP GG1 tumors will be selected and undergo: * PSMA PET with calculation of SUVmax and PRIMARY-Likert score * Whole Exome Sequencing (WES) analysis on diagnostic prostate biopsies * Immunohistochemistry on diagnostic prostate biopsies * Confirmatory biopsy one year after diagnosis, as recommended by international guidelines This prospective, monocentric, single-arm interventional study will assess the predictive accuracy of a multivariable model integrating next-generation imaging and molecular biomarkers to improve risk stratification in active surveillance patients.

CONDITIONS

Official Title

Biological Markers and Advanced Imaging for Prostate Cancer Progression in Active Surveillance

Who Can Participate

Age: 45Years - 80Years
MALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Histologically proven low-risk prostate cancer with PSA ≤10 ng/ml, clinical stage ≤T2a, and biopsy ISUP Grade Group 1
  • Non-metastatic status at study enrollment
  • No prior or current androgen deprivation therapy
  • Ability to understand and sign written informed consent
Not Eligible

You will not qualify if you...

  • Unable to tolerate a PSMA-PET scan
  • Unwillingness to be managed with active surveillance
  • Prior receipt of neoadjuvant or curative-intent therapies
  • Presence of a pacemaker
  • Inability to obtain formalin-fixed paraffin-embedded prostate biopsy samples from the initial biopsy

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

IRCCS Ospedale San Raffaele

Milan, Italy, Italy, 20132

Actively Recruiting

Loading map...

Research Team

G

Giorgio Gandaglia

CONTACT

L

Lucia Dambrosio

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

DIAGNOSTIC

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here